Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

Sirona Biochem Corp V.SBM

Alternate Symbol(s):  SRBCF

Sirona Biochem Corp. is a cosmetic ingredient and drug discovery company with proprietary platform developed at its laboratory facility in France. Through its wholly owned subsidiary TFChem S.A.R.L., the Company specializes in stabilizing carbohydrate molecules. The principal activities of the Company include development of cosmetic and pharmaceutical active ingredients. TFChem develops and markets its GlycoMim technology for pharmaceutical and biotechnology comp anies. TFChem’s proprietary chemistry technology can be applied to the development of several pharmaceutical domains such as cancer, diabetes, pain and inflammation and cardio-vascular diseases. Its cosmetic therapeutic area includes skincare-dark spot corrector (Rx & OTC), cell preservation and repair (including keloid and scar therapy), skincare-anti aging/anti-wrinkle and skincare-cellulite treatment. It has developed an active ingredient, TFC-1067 for the treatment of Dyschromia (Dark spots on the skin).


TSXV:SBM - Post by User

Bullboard Posts
Comment by MirrorWorldManon Sep 14, 2019 1:09pm
103 Views
Post# 30127060

RE:RE:RE:RE:RE:RE:RE:RE:TALK

RE:RE:RE:RE:RE:RE:RE:RE:TALKIntuitively recognition of an incrementally evolving business model by a few investors is quite different than a conscious medium or long term corporate strategic decision. Point is that howie has had little credibility on where or what this company is and where its going but rather seems pushed by whatever environmental factor is present.  Like calliing our international SGLT2 molecule after Wanbang for example so the RoW can license a drug whose generic name is from a chinese company. Looks like howie had little control over anything; and changing his stance on upfronts and pretend its business as usual is naive and arrogant. But whatever the case, he better a least make some deal or the chinese investors will become the latest group of disappointed investors after NA and Germany. 
Bullboard Posts